Note: Ingredients listed on restricted chemical lists
EC/CAS
9004-65-3
Name of the chemical
methylhydroxypropylcellulose
Concentration
N/A
EC/CAS
9003-39-8
Name of the chemical
polyvinylpyrrolidone
Concentration
N/A
General Information
Revision date
2019-08-19
Product name
Metformin Hydrochloride Extended-Release Tablets: 500 mg and 750 mg
Chemical name
N,N-dimethyl-imidodicarbonimidic diamide, monohydrochloride; 1,1- Dimethylbiguanide hydrochloride Structure
1.2.1 Relevant identified uses
Pregnancy
1.2.2. Uses advised against
patients with
Icons in SDS
Company Information
company name
Cadila Healthcare Ltd.
GHS Information
Signal word
Warnings
Section 2
SECTION 2: Hazards identification
Dosage and Adult Dosage Administration: never crush, cut or chew. • The recommended starting dose of metformin hydrochloride extended- release tablets are 500 mg orally once daily with the evening meal. • Increase the dose in increments of 500 mg weekly on the basis of glycemic control and tolerability, up to a maximum of 2,000 mg once daily with the evening meal. • If glycemic control is not achieved with metformin hydrochloride extended-release tablets 2,000 mg once daily, consider a trial of metformin hydrochloride extended-release tablets 1,000 mg twice daily. If higher doses are required, switch to metformin hydrochloride tablets at total daily doses up to 2,550 mg administered in divided daily doses, as described above. • Patients receiving metformin hydrochloride tablets may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once daily. Recommendations for Use in Renal Impairment • Assess renal function prior to initiation of metformin hydrochloride extended-release tablets and periodically thereafter. • Metformin hydrochloride extended-release tablets are contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m2. • Initiation of metformin hydrochloride extended-release tablets in patients with an eGFR between 30 mL/minute/1.73 m2 to 45 mL/minute/1.73 m2 is not recommended. • In patients taking metformin hydrochloride extended-release tablets whose eGFR later falls below 45 mL/min/1.73 m2, assess the benefit risk of continuing therapy. • Discontinue metformin hydrochloride extended-release tablets if the patient’s eGFR later falls below 30 mL/minute/1.73 m2 Discontinuation for Iodinated Contrast Imaging Procedures Discontinue metformin hydrochloride extended-release tablets at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 mL/min/1.73 m2 and 60 mL/min/1.73 m2; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart metformin hydrochloride extended-release tablets if renal function is stable Adverse Effects: The following adverse reactions are also discussed elsewhere in the
2.2 Label elements
Lactic Acidosis • Vitamin B12 Deficiency • Hypoglycemia Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In placebo-controlled trials, 781 patients were administered metformin hydrochloride extended-release tablets. Adverse reactions reported in greater than 5% of the metformin hydrochloride extended-release tablets patients, and that were more common in metformin hydrochloride extended- release tablets- than placebo-treated patients, are listed in Table 2. Table 2 Adverse Reactions from Clinical Trials of Metformin Hydrochloride Extended- Placebo (n=781) (n=195) Diarrhea 10% 3% Nausea/Vomiting 7% 2% Over Dose Effect: Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected. Pregnancy Comments: Limited data with metformin hydrochloride extended-release tablets in pregnant women are not sufficient to determine a drug-Associated risk for major birth defects or miscarriage. Published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk. There are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy No adverse developmental effects were observed when metformin was administered to pregnant Sprague Dawley rats and rabbits during the period of organogenesis at doses up to 2 times and 5times, respectively, a 2,550 mg clinical dose, based on body surface area. The estimated background risk of major birth defects is 6% to 10% in women with pre-gestational diabetes mellitus with an HbA1C >7 and has been reported to be as high as 20% to 25% in women with a HbA1C >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Poorly-controlled diabetes mellitus in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes mellitus increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity. Data Human Data Published data from postmarketing studies have not reported a clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was used during pregnancy. However, these studies cannot definitely establish the absence of any metformin-associated risk because of methodological limitations, including small sample size and inconsistent comparator groups. Animal Data Metformin hydrochloride did not adversely affect development outcomes when administered to pregnant rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 times and 5 times a 2,550 mg clinical dose based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin. Warnings & Precautions Lactic Acidosis • Vitamin B12 Deficiency Metformin may lower vitamin B12 levels. Measure hematological parameters annually and vitamin B12 at 2 to 3 year intervals and manage any abnormalities. • Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues: Increased risk of hypoglycemia when used in combination Drug Interactions: Carbonic anhydrase inhibitors may increase risk of lactic acidosis. Consider more frequent monitoring • Drugs that reduce metformin clearance (such as ranolazine, vandetanib, dolutegravir, and cimetidine) may increase the accumulation of metformin. Consider the benefits and risks of concomitant use • Alcohol can potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake